Guided Therapeutics signs distribution deals to gain access to 86 million new potential patients, hoping to land a win after the FDA refused to accept the company’s premarket approval application.
Georgie-based Guided Therapeutics (OTC:GTHP) hasn’t won many points after announcing increased distribution for its LuViva advanced cervical scanning system.
The device maker last week signed agreements with distributors that open up markets in France, Qatar, Malaysia, Indonesia and Bangladesh, extending the company’s reach to around 86 million women aged 25-64, according to a company statement.
